Genitourinary Cancers

• Castration-resistant prostate cancer: Case presentation: Indications for SABR, treatment planning and delivery techniques
• Castration-resistant prostate cancer: Is there a need for combined medical treatment?
• Oligometastatic prostate cancer - Management options: Initial neo-adjuvant systemic treatment
• Oligometastatic prostate cancer - Management options: The radiation oncologist point of view
• Utility of Gallium-68 PSMA PET/CT Scan for Staging and Treatment of Prostate Cancer in Contemporary Era: Study from Tertiary Care Cancer Centre in...
• Prognostic and predictive clinical factors for progression to castration refractory prostate cancer in patients with hormone sensitive prostate can...
• The gap of frailty value from a community-dwelling population predict oncological outcomes in patients with urological cancers
• Comparison between robot-assisted radical prostatectomy and minimum incision endoscopic radical prostatectomy for high-risk prostate cancer followi...
• The impact of different treatment modalities on toxicity and quality of life for prostate cancer - a real-world study based on WeChat in China
• HoxB13 expression in prostate cancer: clinicopathologic characteristics and role as potential diagnostic marker
• Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for Asian patients with early-sta...
• The linear-quadratic (LQ) model is inappropriate for high doses per fraction owing to _/_ ratio is not a constant: evidence deduced from radiothera...
• Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)
• Prognostic impact of pT3a subclassification based on extent of extraprostatic extension after robot-assisted radical prostatectomy.
• Immunotherapy with dendritic cells derived from bone marrow hematopoietic stems cells inhibited tumor growth on a TRAMP-C1 syngeneic mouse model of...
• Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy.
• A new novel gene ABCC5 promotes castration-resistant prostate cancer progression through ERK carcinogenic pathway
• Docetaxel versus Abiraterone in Newly Diagnosed Metastatic Prostate Cancer : Study from Tertiary Care Cancer Centre in a Developing Country
• Aldo-keto-reductase 1C3 expression in prostate cancer
• LOCALISED CARCINOMA PROSTATE: Intensity Modulated Radiotherapy (IMRT) Followed By Stereotactic Body Radiotherapy (SBRT) Boost: A Feasibility Study...
• Upfront Chemotherapy for High Volume HSPC, Single Institute Experience of Southern Taiwan
• Predictability of intra-fractional prostate motion
• United in Fight against prOstate cancer registry (UFO): treatment patterns and quality of life from a large, multi-center, longitudinal cohort stud...
• Efficacy and Safety of Apalutamide (APA) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN: Asian Sub...
• The change in expression of prostate-specific membrane antigen in circulating tumor cells during treatments for castration-resistant prostate cancer

• « Previous
• 1
• 2
• ...
• 88
• Next »